Israeli Biotech Company Begins Trial For Cancer Immuno-Oncology Solution by rpadmin | Dec 6, 2022 | Nectin
MD Anderson VC Arm Joins $25M Funding Round For Cancer Drug Company by rpadmin | Dec 6, 2022 | Nectin
Nectin Therapeutics Announces Extended Series A Financing to Over $25M and Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors by rpadmin | Dec 6, 2022 | Nectin
Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy by rpadmin | Mar 8, 2022 | Nectin
KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers by rpadmin | Feb 17, 2022 | Kahr, PR Newswire